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Gilles Gasser*
Werner Prize 2015
Abstract: Since the start of our independent research at the Department of Chemistry of the University of Zurich in 
2009, our group has been, among other topics, working on the use of metal complexes in medicinal chemistry. In 
this short review article, we highlight our recent achievements in the use of such compounds to fight the parasitic 
disease schistosomiasis.
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Schistosomiasis
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SNSF Assistant Professor (2010). Gilles 
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(2000), the Syngenta Award for the best 
PhD thesis in Chemistry of the University 
of Neuchâtel (2004), an Alexander von 
Humboldt fellowship (2007) and the 
Werner Prize (2015).
1. Introduction
Thanks notably to the pioneering work 
of Alfred Werner at the University of Zurich 
in the field of coordination chemistry, the 
use of metal complexes as reaction cata-
lysts could be significantly advanced dur-
ing the 20th century.[1] Another less obvious 
field which has undoubtedly profited from 
the research performed by Alfred Werner 
is medicinal chemistry.[2] Although metal 
ions/metal complexes have been employed 
in medicine since ancient times, the use of 
structurally defined metal complexes in 
this field mostly appeared at the beginning 
of the 20th century with the discovery by 
Ehrlich, in collaboration with Sahachiro 
Hata, of the arsenic-containing organome-
tallic complex Arsphenamine (also called 
Salvarsan or Compound 606, see Fig. 1) as 
an agent against syphilis.[3] This compound, 
whose exact structure was only unveiled 
in 2005,[4] was used against this infection 
disease until the discovery of penicillin.[5,6] 
Since then, many other metal complexes 
have been found to be useful in medicinal 
chemistry.[7–10] As surprisingly as it can be 
seen for the non-expert in the field, com-
plexes of Fe, Sn, Bi, Lu, Hg, Sb, Pt, Au or 
As, for example, have been or are approved 
for the treatment of a range of conditions 
in medicine. The majority of the readers 
of this article have most probably used in 
the not-so-distant past the orange mercury-
containing compound Merbromin (notably 
marketed as Mercurochrome) as a topical 
antiseptic (Fig. 1) although mercury is only 
perceived by the general public as a toxic 
heavy metal. Even more surprising is the 
case of As
2
O
3
, which was used, among 
others, by the Borgia family as a homi-
cidal agent in the 15th and 16th centuries, 
but which is approved by the FDA for the 
treatment of relapsed acute promyelocytic 
leukemia under the trade name Trisenox. 
Finally, the metal gold, which is mostly 
associated with luxury, has also found 
 application in medicinal chemistry.  Three 
Au(i) complexes, namely Auranofin (Fig. 
1), Aurothiomalate and Aurothiosulfate 
are approved drugs for the treatment of 
rheumatoid arthritis. Nonetheless, the 
most relevant examples in the field of 
medicinal chemistry are undoubtedly the 
platinum-based anticancer drugs Cisplatin, 
Oxaliplatin and Carboplatin (Fig. 1). 
These metal complexes are currently used 
in more than 50% of the chemotherapeu-
tic treatments, often in combination with 
other drugs.
Despite the impressive success of these 
metal-based drugs, and more generally of 
drugs in all fields of medicine, there is un-
doubtedly still an important need for the 
development of new drugs to either treat 
incurable conditions or to improve the 
current available treatments which, for ex-
ample, can lead to severe side-effects (i.e. 
treatment with Cisplatin). When we started 
our independent research at the University 
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this field of research is based on the pio-
neering work of the groups of the French 
scientists Jaouen, Brocard and Biot. Those 
researchers demonstrated that the addition 
of a ferrocenyl moiety into the structure of 
two known organic drugs, namely the anti-
cancer compound Tamoxifen and the anti-
malarial Chloroquine, to give the so-called 
organometallic complexes Ferrocifens and 
Ferroquine, respectively, allowed for nov-
el, additional mode of actions compared to 
the parent organic drugs (Fig. 3). 
More specifically, the Ferrocifens were 
shown to bind to the estrogen receptor 
similarly to Tamoxifen.[23,24] This compet-
itive binding represses estradiol-mediated 
DNA transcription in the tumor tissue and 
is therefore responsible for the anticancer 
activity of Tamoxifen.[25] However, very 
interestingly, the Ferrocifen with n = 4 
(Fig. 3) was also found to be active against 
breast cancer cell lines lacking this estro-
gen receptor (i.e. ER(–) cell line), contrary 
to Tamoxifen, which is inactive on this cell 
line. This discovery was extremely exciting 
for two reasons: 1) one third of the breast 
cancer patients do not express this recep-
tor, rendering hormone therapy inefficient; 
2) the expression of the estrogen receptor 
sometimes becomes down-regulated under 
Tamoxifen treatment, turning the drug in-
effective. This interesting observation was 
explained by the specific presence of the 
organometallic moiety. Indeed, a redox 
activation was found to be responsible for 
the observed cytotoxicity in ER(–) cancer 
cells.[26] As shown in Scheme 1, the ac-
tive metabolite hydroxyferrocifen can be 
readily oxidized to give a quinone methide 
intermediate.[26] This quinine methide can 
be then attacked by nucleophiles such as 
glutathione and nucleobases. This leads to 
the general toxicity and mutagenic poten-
tial of this compound. This mode of action 
was further confirmed when the research-
ers could prepare and biologically evalu-
ate the ruthenocene analogue of the active 
Ferrocifen (see Fig. 3 – this compound will 
be called Ruthenocifen in this review arti-
cle). These two complexes are isostructural 
but, compared to Ferrocifen, Ruthenocifen 
is not redox active. Hence, as expected, 
Ruthenocifen was found to be active only 
on ER(+) breast cancer cells but not on 
ER(–) cell lines.[27] 
In the case of the antimalarial drug 
candidate Ferroquine, the presence of the 
ferrocene moiety was found to enable 
drug resistance to be overcome. Indeed, 
Ferroquine is active against chloroquine-
resistant parasitic strains. One of the expla-
nations for this observation is again redox 
chemistry. In addition to having a similar 
mode of action to Chloroquine, Ferroquine 
can also produce reactive oxidative species 
(ROS), which kill the parasites resistant to 
Chloroquine.[28,29] As for the Ferrocifens, 
of Zurich, our group decided to primarily 
focus its attention on two diseases, namely 
cancer and schistosomiasis. While the for-
mer disease does not need to be presented, 
the latter is, very surprisingly, unknown 
to the general public. Schistosomiasis, 
also known as bilharziasis, is a parasitic 
disease which is responsible for 207 mil-
lion infections each year in tropical and 
subtropical regions of sub-Saharan Africa, 
Asia and America.[11] In fact, it is the sec-
ond most prevalent parasitic disease in the 
world after malaria. The number of deaths 
associated with this disease significantly 
varies depending on the studies (between 
11’700 and 280’000).[12–14] More specifi-
cally, schistosomiasis is caused by para-
sitic worms (schistosomes) with a com-
plex life cycle.[15] There are five species 
of schistosomes (i.e. S. haematobium, S. 
intercalatum, S. japonicum, S. mansoni, 
and S. mekongi), which are accountable for 
human infections leading either to intesti-
nal or urogenital schistosomiasis.[16] This 
disease is often associated with liver dam-
age resulting in swelling of the abdomen of 
the person affected. While this disease can 
be treated at present, with the organic drug 
Praziquantel (PZQ, Fig. 2), the therapeutic 
situation is far from ideal. Reduced sus-
ceptibility to PZQ has been reported, sug-
gesting that this drug could become (much 
less) effective in the future.[17–19] This fact 
is extremely worrying since there is no cur-
rent alternative to PZQ. In fact, since PZQ 
was marketed in 1984, no new drug has 
entered the market to fight this disease,[20] 
while the number of chemotherapeutic 
treatments against this disease gradually 
increased from 12.4 million people in 
2006 to over 42.1 million people treated in 
2012.[21,22] It is anticipated that this num-
ber will further increase in the future.[21,22] 
These distressing facts were the reasons 
for the start of our program on the evalua-
tion of novel organometallic complexes as 
novel antischistosomal drug candidates.[11]
The concept that we have decided to 
employ to provide new lead structures in 
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organometallic compounds to fight schis-
tosomiasis.[11]
2. Organometallic-based 
Antischistosomal Drug Candidates
Obviously, the first idea which came 
to our mind was to derivatize PZQ with 
ferrocene. Thus, as shown in Fig. 4, we 
prepared and characterized 18 ferrocenyl 
derivatives of PZQ. As anticipated, us-
ing LC-MS techniques, these compounds 
were found to be extremely stable in hu-
man plasma. However, the bioactivity of 
these complexes was found to be relative-
ly disappointing. Out of the 18 ferrocenyl 
derivatives in our hands, only four com-
pounds were found to have an antischisto-
somal activity at 30 µg/mL in vitro against 
S. mansoni.[33]
We then evaluated the antischistosomal 
potential of two new chromium tricarbonyl 
derivatives of PZQ (1 and 2, Fig. 4).[34] One 
of the rationales behind the choice of this 
derivatization was that PZQ is, in vivo, 
rapidly metabolized to the much less ac-
tive metabolite PZQ-OH (Fig. 2). We were 
hoping that this organometallic derivatiza-
tion would reduce this conversion. Of note, 
as discussed in more detail in our recent 
articles, the amount of chromium used in 
our studies is far below the threshold of 
intrinsic toxicity of this metal.[11,34,35] The 
first biological results were found to be 
extremely promising. Both organometallic 
compounds were found to have a remark-
able antischistosomal activity (0.25 µM 
for 1 and 0.27 µM for 2), comparable to 
the parent organic drug PZQ (0.1 µM). 
Also, both compounds showed a promis-
ing selectivity for parasites since they had 
mainly no activity on the cervical cancer 
(HeLa) and non-cancerous (MRC-5) cell 
lines (IC
50
 >100 µM).[34]
the replacement of the ferrocenyl moiety 
by a ruthenocene unit to give Ruthenoquine 
(Fig. 3) led to a decreased potency due to 
the absence of redox chemistry of the lat-
ter. Of important note, Ferroquine is the 
most advanced organometallic compound 
in industrial phase (Sanofi owns the rights 
for this drug candidate). This drug candi-
date should enter into phase IIb clinical tri-
als this year.[30–32]
With this concept in mind, our group 
prepared and evaluated a series of organo-
metallic compounds in collaboration with 
the group of Prof. Jennifer Keiser at the 
Swiss Tropical and Public Health Institute 
in Basel. In this short review, we present 
our recent achievements in this field of 
research. Of note, this topic was recently 
reviewed by our group and we invite the 
reader of this article to refer to this review 
for a more detailed description of the use of 
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Scheme 1. Redox activation of Ferrocifens as proposed by Jaouen et al. The ferrocenyl moiety 
serves as a ‘redox antenna’, following oxidation and proton abstraction, a quinone methide is 
formed, which is readily attacked by nucleophiles at the positions indicated by arrows. Scheme 
taken with permission from ref. [25]. Copyright American Chemical Society.
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These promising results encouraged us 
to explore in more detail the (metabolic) 
behavior of these organometallic com-
pounds. First of all, we could demonstrate 
that these complexes were stable for 24 h 
at 37 °C in human plasma.[34] We could 
also show, using human liver microsomes, 
that their metabolic profile was, surpris-
ingly, relatively different to PZQ and to 
one another (Scheme 2).[35] On one hand, 
1 is primarily demetallated to PZQ or 
hydroxylated to cis-4-PZQ-OH. On the 
other hand, only minor demetallation and 
hydroxylation were observed for 2. The 
major metabolite of 2 was identified as 
[(η6-praziquanamine)Cr(CO)
3
]. This me-
tabolite is formed after cleavage of the cy-
clohexanoyl moiety.[35]
Another important study that we under-
took to gain more insight into the mode of 
action of these organometallic compounds 
was to assess if the enantiomers/diastereo-
isomers of compounds 1 and 2 had similar 
biological activity. Indeed, PZQ is given 
to infected persons as a racemic mixture 
although only one of its enantiomers ((R)-
PZQ) has an antischistosomal activity in 
vitro. In addition, this enantiomer is as-
sumed to have fewer adverse events than 
the (S)-PZQ enantiomer.[36] With this in 
mind, we prepared and evaluated the in 
vitro antischistosomal activity against 
adult S. mansoni of the optically pure 
(η6-PZQ)Cr(CO)
3 
derivatives (R,R
P
)-1, 
(S,S
P
)-1, (S,R
P
)-2 and (R,S
P
)-2 (Scheme 
3). Interestingly, only the two complexes 
containing the active PZQ ((R)-PZQ), 
namely (R,R
P
)-1 and (R,S
P
)-2 were found 
to be active. This observation, although not 
a definitive proof, suggests that the (R)-
enantiomers of (η6-PZQ)Cr(CO)
3 
have the 
same target as PZQ.
With all this information available, we 
then evaluated the in vivo potential of these 
two compounds. For this purpose, a race-
mic mixture of compounds 1 and 2 (i.e. 
as for PZQ) was given to mice harboring 
adult S. mansoni. Unfortunately, contrary 
to expectations, relatively low total worm 
burden reductions of 24% and 29%, re-
spectively, were obtained with single dos-
es of 400 mg/kg of 1 and 2. For compari-
son purposes, PZQ reached a total worm 
burden reduction of 96% with the same 
dosage.[35] These relatively disappointing 
results could be explained by distribution 
problems or protein binding.[11,35]
Another route that our group has been 
exploring to discover novel lead antischis-
tosomal drug candidates is drug-repurpos-
ing. This strategy is based on the use of an 
already known and/or an approved drug to 
treat a (completely) different disease.[37] In 
collaboration with Prof. Christophe Biot 
and Prof. Jennifer Keiser, we evaluated the 
potential of the organometallic antimalari-
al drug candidates discussed above, name-
ly Ferroquine and Ruthenoquine (Fig. 3) as 
antischistosomal agents.[38] For compari-
son purposes, Hydroxyl-Ferroquine and 
the known antimalarial drugs Chloroquine 
and Mefloquine were employed as refer-
ence compounds (Fig. 3). The rationale 
behind the choice of such derivatives 
is that the parasites in both malaria and 
schistosomiasis are blood-feeding and 
that they share the heme degradation path-
way.[11] These facts could imply that drug 
candidates could have similar targets.[39] 
Unfortunately, our in vivo experiments 
revealed only a weak antischistosomal ac-
tivity of these organometallic compounds. 
The highest total worm burden reduction 
was observed for the antimalarial drug 
candidate Ferroquine (19.4% and 35.6% 
when treated with 200 and 800 mg/kg, 
respectively).[38] Despite these relatively 
disappointing results, we strongly believe 
that other organometallic drug candidates, 
notably those already studied for their an-
tiparasitic activity, should be evaluated as 
antischistosomal agents.
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3. Conclusions
It is difficult to predict if an organome-
tallic complex will be used one day to treat 
schistosomiasis. However, we strongly be-
lieve that it would be a mistake to overlook 
such compounds as potential antischisto-
somal drug candidates, especially consid-
ering the great promise that Ferroquine 
is bringing to the field of malaria and, 
more generally to the field of medicinal 
organometallic chemistry. Since our last 
publication on this subject, our group has 
been actively working to unveil novel lead 
compounds. Very recently, in preliminary 
experiments, we could demonstrate that a 
novel ferrocenyl complex had a high activ-
ity in vivo and, importantly, did not engen-
der any toxic effects on mice. These results 
hold great promise and will be published in 
the near future.
Acknowledgements
I would like first to thank the Swiss 
Chemical Society for the award of the Werner 
Prize 2015. I am extremely grateful to all 
my past and current students and post-docs 
for their tremendous work – thanks so much 
to Malay, Tanmaya, Riccardo, Loganathan, 
Konstantis, Giuseppe, Phuc, Anna, Philipp, 
Vanessa, Cristina, Jeannine, Carla, Giuliana, 
Sandro, Angelo, Sandra, Lea, Assia, Seraina, 
Elisa and Luciano. I would like also to take this 
opportunity to thank all the mentors who have 
supervised me over my career, namely Prof. 
Helen Stoeckli-Evans, Prof. Leone Spiccia, 
Prof. Nils Metzler-Nolte and Prof. Roger 
Alberto – thanks so much for your feedback, 
advice, help and support. Many thanks go also 
to the many scientists I am collaborating with, 
especially Prof. Jennifer Keiser, who is closely 
involved in the topic presented in this review 
article. Finally, I would like to acknowledge 
the financial support from the Swiss National 
Science Foundation, the University of Zurich, 
the  Stiftung für Wissenschaftliche Forschung 
of the University of Zurich, the Novartis Jubilee 
Foundation, the UBS Promedica Stiftung, the 
Forschungskredit of the University of Zurich, 
the COST Action CM1105 and the Swiss 
Government Scholarship Program.
Received: June 11, 2015 
 
[1] K.-H. Ernst, F. R. W. P. Wild, O. Blacque, H. 
Berke, Angew. Chem. Int. Ed. 2011, 50, 10780.
[2] N. P. E. Barry, P. J. Sadler, Pure & Applied 
Chem. 2014, 86, 1897.
[3] ‘Concepts and Models in Bioinorganic 
Chemistry’, Eds. H.-B. Kraatz, N. Metzler-
Nolte, Wiley-VCH, Weinhein, 2006.
[4] N. C. Lloyd, H. W. Morgan, B. K. Nicholson, 
R. S. Ronimus, Angew. Chem. Int. Ed. 2005, 44, 
941. 
[5] S. Gibaud, G. Jaouen, in ‘Medicinal Organo-
metallic Chemistry’, Eds. G. Jaouen, N. 
Metzler-Nolte, Springer-Verlag, Heidelberg, 
2010, p. 1.
[6] M. Patra, G. Gasser, N. Metzler-Nolte, Dalton 
Trans. 2012, 41, 6350.
[7] N. P. E. Barry, P. J. Sadler, Chem. Commun. 
2013, 49, 5106.
[8] J. C. Dabrowiak, ‘Metals in Medicine’, John 
Wiley & Sons Ltd, Chichester, 2009.
[9] E. Alessio, ‘Bioinorganic Medicinal Chemistry’, 
Wiley-VCH Verlag, Weinheim, 2011.
[10] J. L. Sessler, S. R. Doctrow, T. J. McMurry, S. J. 
Lippard, ‘Medicinal Inorganic Chemistry’, vol. 
903, American Chemical Society, Washington, 
D.C, 2005.
[11] J. Hess, J. Keiser, G. Gasser, Future. Med. 
Chem. 2015, 8, 821.
[12] R. Liu, H.-F. Dong, Y. Guo, Q.-P. Zhao, M.-S. 
Jiang, Parasites & Vectors 2011, 4, 201.
[13] P. J. Hotez, A. Fenwick, L. Savioli, D. H. 
Molyneux, Lancet 2009, 373, 1570.
[14] A. A. Sayed, A. Simeonov, C. J. Thomas, J. 
Inglese, C. P. Austin, D. L. Williams, Nat. Med. 
2008, 407.
[15] E. F. Lee, N. D. Young, N. T. Y. Lim, R. B. 
Gasser, W. D. Fairlie, Trends in Parasitology 
2014, 30, 75.
[16] D. G. Colley, A. L. Bustinduy, W. E. Secor, C. 
H. King, Lancet 2014, 383, 2253.
[17] M. Ismail, S. Botros, A. Metwally, S. William, 
A. Farghally, L. F. Tao, T. A. Day, J. L. Bennett, 
Am. J. Trop. Med. Hyg. 1999, 60, 932.
[18] S. D. Melman, M. L. Steinauer, C. Cunningham, 
L. S. Kubatko, I. N. Mwangi, N. B. Wynn, M. 
W. Mutuku, D. M. S. Karanja, D. G. Colley, C. 
L. Black, W. E. Secor, G. M. Mkoji, E. S. Loker, 
PLoS Negl. Trop. Dis. 2009, 3, e504.
[19] R. M. Greenberg, Parasitology 2013, 140, 
1534.
[20] S. A. L. Thétiot-Laurent, J. Boissier, A. Robert, 
B. Meunier, Angew. Chem. Int. Ed. 2013, 52, 
7936.
[21] WHO Fact sheet No. 115, Document available 
at http://www.who.int/mediacentre/factsheets/
fs115/en//# ; Updated May 2015.
[22] D. Rollinson, S. Knopp, S. Levitz, J. R. 
Stothard, L.-A. Tchuem Tchuenté, A. Garba, 
K. A. Mohammed, N. Schur, B. Person, D. G. 
Colley, J. Utzinger, Acta Tropica 2013, 128, 
423.
[23] G. Jaouen, S. Top, A. Vessières, in 
‘Bioorganometallics: Biomolecules, Labeling, 
Medicine’, Ed. G. Jaouen, Wiley-VCH Verlag 
GmbH & Co., Weinheim, 2006.
[24] E. A. Hillard, A. Vessières, G. Jaouen, in 
‘Medicinal Organometallic Chemistry’, Eds. 
G. Jaouen, N. Metzler-Nolte, Springer-Verlag, 
Heidelberg, 2010, Vol. 32, p 81.
[25] G. Gasser, I. Ott, N. Metzler-Nolte, J. Med. 
Chem. 2011, 54, 3.
[26] E. Hillard, A. Vessiere, L. Thouin, G. Jaouen, C. 
Amatore, Angew. Chem. Int. Ed. 2006, 45, 285.
[27] P. Pigeon, S. Top, A. Vessières, M. Huché, E. 
Hillard, E. Salomon, G. Jaouen, J. Med. Chem. 
2005, 48, 2814.
[28] F. Dubar, T. J. Egan, B. Pradines, D. Kuter, K. 
K. Ncokazi, D. Forge, J.-F. Paul, C. Pierrot, H. 
Kalamou, J. Khalife, E. Buisine, C. Rogier, H. 
Vezin, I. Forfar, C. Slomianny, X. Trivelli, S. 
Kapishnikov, L. Leiserowitz, D. Dive, C. Biot, 
ACS Chem. Biol. 2012, 6, 275.
[29] F. Dubar, C. Slomianny, J. Khalife, D. Dive, 
H. Kalamou, Y. Guérardel, P. Grellier, C. Biot, 
Angew. Chem. Int. Ed. 2013, 52, 7690.
[30] T. N. C. Wells, R. H. van Huijsduijnen, W. C. 
Van Voorhis, Nat. Rev. Drug Discov. 2015, 14, 
424.
[31] C. Biot, D. Dive, in ‘Medicinal Organometallic 
Chemistry’, Eds. G. Jaouen, N. Metzler-Nolte, 
Springer-Verlag, Heidelberg, 2010, Vol. 32, p 
155.
[32] D. Dive, C. Biot, ChemMedChem 2008, 3, 383 
[33] M. Patra, K. Ingram, V. Pierroz, S. Ferrari, B. 
Spingler, J. Keiser, G. Gasser, J. Med. Chem. 
2012, 55, 8790.
[34] M. Patra, K. Ingram, V. Pierroz, S. Ferrari, B. 
Spingler, R. B. Gasser, J. Keiser, G. Gasser, 
Chem. Eur. J. 2013, 19, 2232.
[35] M. Patra, K. Ingram, A. Leonidova, V. Pierroz, 
S. Ferrari, M. Robertson, M. H. Todd, J. Keiser, 
G. Gasser, J. Med. Chem. 2013, 56, 9192.
[36] M. Woelfle, J.-P. Seerden, J. de Gooijer, K. 
Pouwer, P. Olliaro, M. H. Todd, PLoS Negl. 
Trop. Dis. 2011, 5, e1260.
[37] G. Panic, U. Duthaler, B. Speich, J. Keiser, Int. 
J. Parasitol. Drugs Drug Resist. 2014, 4, 185.
[38] J. Keiser, M. Vargas, R. Rubbiani, G. Gasser, C. 
Biot, Parasites & Vectors 2014, 7, 424.
[39] J. Keiser, J. Utzinger, Curr. Pharm. Des. 2012, 
18, 3531.
N
O
(R)
N
O
CrOC
OC CO
H
N
O
(S)
N
O
CrOC
OC CO
H
(S, Sp)-1
S-PZQ
N
O
(S)
N
O
CrOC
OC CO
H
(S, Rp)-2 (R, Sp)-2
(R, Rp)-1
N
O
(R)
N
CrOC
OC CO
H
Enantiomers
Enantiomers
DiastereomersDiastereomers Diastereomers
R-PZQ
Cr(CO)6 Cr(CO)6
140°C 140°C
N
O
(S)
N
O
H
N
O
(R)
N
O
H
Scheme 3. Synthesis of the optically pure (η6-PZQ)Cr(CO)3 derivatives starting from S-PZQ and 
R-PZQ. Scheme taken with permission from ref. [35]. Copyright American Chemical Society.
